Certara (CERT) and selling shareholders intend to raise an estimated $500 million in an IPO of its common stock, according to an S-1 registration statement.
Princeton, New Jersey-based Certara was founded to develop biosimulation software to assist biopharmaceutical companies in conducting virtual trials to predict how drugs might behave in patients.
Management is headed by William Feehery, Ph.D, who has been with the firm since June 2019 and was previously president of DuPont Industrial Biosciences
Below is a brief overview video of Certara:
The firm’s primary markets include:
- Regulatory Science
- Market Access
Certara has received at least $510 million from investors including EQT AB and Arsenal Investors.
The company pursues biopharmaceutical firms via a direct sales and marketing approach and had more 1,600 biopharma companies and academic institutions in 60 countries as customers as of the end of 2019.
Additionally, numerous regulatory authorities are customers, including the